2015 American Transplant Congress
Evaluation of Medication Regimen Complexity Over Time Following Heart Re-Transplantation
Medication regimen complexity (MRC) includes many characteristics of a drug regimen. Previously, we showed that MRC is high and persists over time after primary heart…2015 American Transplant Congress
The Correlation Between Donor Specific Antibodies and Heart Transplant Rejection
The presence of donor specific HLA antibodies (DSA) has been shown to be detrimental to heart transplant (HTx) survival. Virtual crossmatching (VXM) offers a rapid…2015 American Transplant Congress
Plasma Levels of Donor-Derived Cell-Free DNA Increase With Rejection and Often Decrease After Treatment in Organ Transplant Recipients
1CareDx, Inc, Brisbane, CA; 2Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a potential biomarker of acute cellular rejection (ACR) in organ transplant recipients. dd-cfDNA levels in longitudinal plasma samples from…2015 American Transplant Congress
C1q Reactivity and IgG Subtypes After HLA Antibody Removal Therapy With Carfilzomib in Thoracic Transplant Recipients
Univ of Pittsburgh, Pittsburgh.
Conventional therapies for antibody removal consisting of plasma exchange with IVIG and Rituximab are partially effective in desensitization protocols and for treatment of antibody mediated…2015 American Transplant Congress
Effects of Anti-Human Leukocyte Antigen Antibody After Heart Transplantation
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The development of donor-specific antibodies (DSA) after heart transplant has been correlated to the subsequent development of graft rejection. The development of DSA are…
- « Previous Page
- 1
- …
- 28
- 29
- 30